At the time of writing, Jazz Pharmaceuticals plc [JAZZ] stock is trading at $112.3, up 0.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JAZZ shares have gain 2.90% over the last week, with a monthly amount glided 1.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on July 15, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $152. Previously, UBS upgraded its rating to Buy on March 07, 2025, and elevated its price target to $179. On February 26, 2025, downgrade downgraded it’s rating to Neutral. Wells Fargo upgraded its rating to a Overweight and increased its price target to $170 on February 13, 2025. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $175 on December 12, 2024. Goldman started tracking with a Buy rating for this stock on June 05, 2024, and assigned it a price target of $169. In a note dated January 03, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $160 on this stock.
For the past year, the stock price of Jazz Pharmaceuticals plc fluctuated between $95.49 and $148.06. Currently, Wall Street analysts expect the stock to reach $194 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $112.3 at the most recent close of the market. An investor can expect a potential return of 72.75% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
According to Jazz Pharmaceuticals plc [NASDAQ:JAZZ], the company’s sales were 4.06B for trailing twelve months, which represents an -0.46% plunge. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 111.24 points at the first support level, and at 110.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 113.24, and for the 2nd resistance point, it is at 114.19.
Ratios To Look Out For
It is important to note that Jazz Pharmaceuticals plc [NASDAQ:JAZZ] has a current ratio of 3.38. As well, the Quick Ratio is 2.97, while the Cash Ratio is 1.52. Considering the valuation of this stock, the price to sales ratio is 1.67, the price to book ratio is 1.66 and price to earnings (TTM) ratio is 15.14.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Jul 01 ’25 when 1000.0 shares were sold. Officer, COZADD BRUCE C completed a deal on Jul 01 ’25 to buy 1000.0 shares. Meanwhile, Chairman & CEO COZADD BRUCE C sold 500.0 shares on Jun 03 ’25.
